Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Kairos Pharma, Ltd. (KAPA – Research Report) and keeping the price target at $12.00.
Joseph Pantginis has given his Buy rating due to a combination of factors that highlight Kairos Pharma’s promising oncology pipeline and strategic advancements. The company is advancing its lead asset, ENV-105, which targets cancer drug resistance and immune suppression checkpoints. This asset is currently in clinical trials for metastatic castration-resistant prostate cancer (mCRPC) and non-small cell lung cancer (NSCLC), with significant data readouts expected in 2025.
The anticipated interim Phase 2 data for ENV-105 in mCRPC is seen as a critical de-risking event for investors, potentially unlocking further opportunities in treating various cancer types. Additionally, Kairos’s exploration of endoglin upregulation as a resistance mechanism across multiple tumor types underscores the broader applicability of their approach. The company’s robust pipeline of preclinical candidates targeting immune checkpoints further supports the potential for long-term growth and innovation in cancer treatment.
Pantginis covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Cytokinetics, and Actinium Pharmaceuticals. According to TipRanks, Pantginis has an average return of -23.2% and a 21.48% success rate on recommended stocks.
In another report released on March 31, Maxim Group also reiterated a Buy rating on the stock with a $4.00 price target.